Document is current
Any future updates will be listed below
-
Authors
Damien, Barikissou Georgia
Sode, Akoeugnigan Idelphonse
Bocossa, Daniel
Elanga-Ndille, Emmanuel
Aguemon, Badirou
Corbel, Vincent
Henry, Marie-Claire
Glèlè Kakaï, Romain Lucas
Remoué, Franck
-
Funding
Funding for this research was provided by:
World Bank via the Booster Programme for Malaria Control in Africa and Malaria National Control Program of Benin and IRD (No. 555/MS/DC/SGM/DNPS/PNLP/PALP/DNP (30/12/2010), No. 555/MS/DC/SGM/DNPS/PNLP/PALP/DNP (30/12/2010), No. 555/MS/DC/SGM/DNPS/PNLP/PALP/DNP (30/12/2010), No. 555/MS/DC/SGM/DNPS/PNLP/PALP/DNP (30/12/2010), No. 555/MS/DC/SGM/DNPS/PNLP/PALP/DNP (30/12/2010))
- License Information
-
More Information
Article History
Received: 30 April 2022
Accepted: 16 August 2022
First Online: 16 September 2022
Declarations
:
: The data were collected in accordance with the Declaration of Helsinki. Ethics clearance for the study was obtained from the National Ethical Committee for Medical Research in Benin (CNERS, Number 003, 24 March 2011, Institutional Review Board No. 00006860) and Institut de Recherche pour le Développement (IRD)’s consultative committee for deontology and ethics (CCDE).Written informed consent to participate in the study was obtained from the parent or legal guardian of children under five. All sick children, whether or not they were participating in the study, were treated by medical staff based on an integrated management of childhood illness strategy during the investigation. Specifically, the malaria cases were treated with artemether–lumefantrine, according to NMCP recommendations in Benin.
: Not applicable
: The authors declare that they have no competing interests.
